Biogen and Xbrane announce commercialization and license agreement for biosimilar to treat rheumatoid arthritis
Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
UCB plans to submit regulatory applications in Q3 2022
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
The platform has seen an overall growth of 84% in the number of people seeking consultations for skin-related issues
Second interchangeable biosimilar product approved by agency
Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Subscribe To Our Newsletter & Stay Updated